Winning Health Technology Group Co., Ltd.

SZSE:300253 Stock Report

Market Cap: CN¥16.4b

Winning Health Technology Group Valuation

Is 300253 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300253 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300253 (CN¥7.63) is trading above our estimate of fair value (CN¥0.03)

Significantly Below Fair Value: 300253 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300253?

Key metric: As 300253 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 300253. This is calculated by dividing 300253's market cap by their current earnings.
What is 300253's PE Ratio?
PE Ratio45.5x
EarningsCN¥360.25m
Market CapCN¥16.38b

Price to Earnings Ratio vs Peers

How does 300253's PE Ratio compare to its peers?

The above table shows the PE ratio for 300253 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average82x
300288 Longmaster Information & Technology
88.1xn/aCN¥5.0b
300550 Heren HealthLtd
137.8xn/aCN¥3.7b
000638 Vanfund Urban Investment and Development
83.7xn/aCN¥1.7b
600529 Shandong Pharmaceutical GlassLtd
18.5x18.4%CN¥16.3b
300253 Winning Health Technology Group
45.5x34.9%CN¥16.4b

Price-To-Earnings vs Peers: 300253 is good value based on its Price-To-Earnings Ratio (45.5x) compared to the peer average (82x).

Price to Earnings Ratio vs Industry

How does 300253's PE Ratio compare vs other companies in the Asian Healthcare Services Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
300253 45.5xIndustry Avg. 23.7xNo. of Companies5PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 300253 is expensive based on its Price-To-Earnings Ratio (45.5x) compared to the Asian Healthcare Services industry average (23.7x).

Price to Earnings Ratio vs Fair Ratio

What is 300253's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300253 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio45.5x
Fair PE Ratio37.2x

Price-To-Earnings vs Fair Ratio: 300253 is expensive based on its Price-To-Earnings Ratio (45.5x) compared to the estimated Fair Price-To-Earnings Ratio (37.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 300253 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥7.63
CN¥8.83
+15.7%
12.2%CN¥10.20CN¥7.50n/a4
Nov ’25CN¥7.35
CN¥8.83
+20.1%
12.2%CN¥10.20CN¥7.50n/a4
Oct ’25CN¥7.39
CN¥7.22
-2.2%
15.8%CN¥8.11CN¥5.00n/a5
Sep ’25CN¥5.45
CN¥8.14
+49.4%
24.8%CN¥11.20CN¥5.00n/a5
Aug ’25CN¥5.56
CN¥8.91
+60.3%
23.5%CN¥11.20CN¥5.00n/a5
Jul ’25CN¥5.87
CN¥8.91
+51.9%
23.5%CN¥11.20CN¥5.00n/a5
Jun ’25CN¥6.20
CN¥8.91
+43.8%
23.5%CN¥11.20CN¥5.00n/a5
May ’25CN¥6.89
CN¥8.99
+30.5%
24.3%CN¥11.60CN¥5.00n/a5
Apr ’25CN¥7.35
CN¥8.62
+17.3%
27.6%CN¥11.60CN¥5.00n/a5
Mar ’25CN¥7.15
CN¥7.88
+10.2%
26.4%CN¥10.00CN¥5.00n/a4
Feb ’25CN¥5.75
CN¥7.88
+37.0%
26.4%CN¥10.00CN¥5.00n/a4
Jan ’25CN¥7.19
CN¥8.08
+12.4%
22.5%CN¥10.00CN¥5.80n/a4
Dec ’24CN¥7.79
CN¥8.14
+4.5%
20.0%CN¥10.00CN¥5.80n/a5
Nov ’24CN¥7.46
CN¥9.37
+25.6%
30.6%CN¥15.00CN¥6.30CN¥7.356
Oct ’24CN¥7.29
CN¥10.34
+41.9%
31.8%CN¥15.00CN¥6.30CN¥7.396
Sep ’24CN¥7.25
CN¥10.34
+42.6%
31.8%CN¥15.00CN¥6.30CN¥5.456
Aug ’24CN¥7.46
CN¥12.22
+63.9%
26.1%CN¥15.12CN¥7.10CN¥5.565
Jul ’24CN¥10.82
CN¥12.35
+14.2%
23.7%CN¥15.12CN¥7.10CN¥5.876
Jun ’24CN¥10.20
CN¥12.35
+21.1%
23.7%CN¥15.12CN¥7.10CN¥6.206
May ’24CN¥11.27
CN¥12.35
+9.6%
23.7%CN¥15.12CN¥7.10CN¥6.896
Apr ’24CN¥13.87
CN¥9.78
-29.5%
25.5%CN¥13.00CN¥6.70CN¥7.355
Mar ’24CN¥10.24
CN¥9.78
-4.5%
25.5%CN¥13.00CN¥6.70CN¥7.155
Feb ’24CN¥10.94
CN¥9.78
-10.6%
25.5%CN¥13.00CN¥6.70CN¥5.755
Jan ’24CN¥10.28
CN¥9.98
-2.9%
27.7%CN¥14.00CN¥6.70CN¥7.195
Dec ’23CN¥9.23
CN¥10.04
+8.8%
25.2%CN¥14.00CN¥6.70CN¥7.796
Nov ’23CN¥9.69
CN¥9.61
-0.9%
26.8%CN¥14.00CN¥6.70CN¥7.467

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Shenzhen Lifotronic Technology

CN¥6.7b

Research, develops, manufactures, and markets medical devices for diagnostics, clinical medicine, skin, and human health related purposes in China.

688389

CN¥15.53

7D

-5.8%

1Y

-34.9%

Chison Medical Technologies

CN¥2.7b

Manufactures and sells diagnostic ultrasound systems in China and internationally.

688358

CN¥24.06

7D

-8.2%

1Y

-44.8%

Winner Medical

CN¥19.7b

Engages in the research and development, manufacture, and marketing of cotton-based medical dressings and medical disposables, and consumer products in China.

300888

CN¥33.90

7D

5.4%

1Y

-14.7%